CG Oncology Inc. Common s... (CGON)
22.28
0.76 (3.53%)
At close: Apr 25, 2025, 3:59 PM
24.04
7.90%
After-hours: Apr 25, 2025, 05:56 PM EDT
Company Description
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CG Oncology Inc. Common stock
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Arthur Kuan |
Contact Details
Address: No Address available No city data available, Delaware United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001991792 |
| CUSIP Number | 156944100 |
| ISIN Number | US1569441009 |
| Employer ID | 37-1611499 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | Chairman & Chief Executive Officer |
| Ambaw Bellete M.S. | President & Chief Operating Officer |
| Corleen M. Roche | Chief Financial Officer & Secretary |
| Amy Steele | Vice President of Finance, Accounting & Administration |
| Bing Kung | Vice President of Corporate Development |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
| Joshua F. Patterson | General Counsel & Chief Compliance Officer |
| Sarah Connors | Vice President of Communications & Patient Advocacy |
| Swapnil Bhargava Ph.D. | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Mar 28, 2025 | S-3ASR | Automatic shelf registration statement of securiti... |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 4 | Filing |